Applying Brave

Science to

Diseases
and Conditions

TD is associated with prolonged use of antipsychotic medication that may be necessary to treat individuals living with mental illnesses, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder. Treatment with antipsychotics are thought to result in irregular dopamine signaling in a region of the brain that controls movement.

There are approximately 600,000 people in the United States living with TD, and approximately 65% have not yet been diagnosed.

Neurocrine Is Proud to Support TD Awareness >

See What We’ve Developed >

HD is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes motor, cognitive, and psychiatric symptoms. Symptoms generally appear between the ages of 30 and 50 years and worsen over a 10- to 25-year period. HD is estimated to affect approximately 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease.

Chorea can affect various body parts and interfere with motor coordination, gait, swallowing, and speech. HD chorea can impact all areas of daily life for patients. As chorea worsens, the ability to function becomes more difficult.

See What We’ve Developed >

Approximately 15% of the estimated 600,000 to 1 million people living in the U.S. diagnosed with cerebral palsy live with dyskinesia (uncontrollable muscle movements).

There are no approved treatments for DCP.

See What We Are Working On >

EE-CSWS typical onset occurs between the ages of two and four years old, with seizures occurring primarily during sleep. The seizures interfere with processes critical to learning and memory. Diagnosis of EE-CSWS is based on a unique electroencephalogram (EEG) pattern of electrical status epilepticus during sleep (ESES), together with cognitive stagnation and regression. Following puberty, seizure frequency tends to decline, however, developmental delays often remain.

EE-CSWS impacts less than 2% of children living with epilepsy worldwide. There is currently no approved treatment for the disorder.

See What We Are Working On >

SCN8A-DEE causes a range of symptoms including severe epilepsy, early onset developmental delay, cognitive impairment, and other medical challenges. Typical onset occurs around 4 months of age.

There are no approved therapies for this form of pediatric epilepsy.

As one of the leading causes of disability worldwide, schizophrenia often results in significant emotional burden for those who experience symptoms, as well as their family and friends. It impacts approximately 24 million people worldwide. Approximately 33% of patients with schizophrenia fail to respond to current antipsychotic therapy.

See What We Are Working On >

MDD is characterized by a persistently depressed mood, loss of interest, lack of enjoyment in daily activities, and decreased energy that can impact normal daily functioning, relationships, and overall quality of life. Of the more than 16 million people in the U.S. who live with MDD, about one-third do not respond to available antidepressants.

See What We Are Working On >

Symptoms of endometriosis include painful periods, pelvic pain between periods, and pain with sex. Estrogen fuels the growth of lesions that can occur on the ovaries, the fallopian tubes, or other areas near the uterus, such as the bowel or bladder.

According to researchers, 7.5 million women in the U.S. are diagnosed with endometriosis, with 3 million diagnosed with moderate to severe endometriosis.

See What We’ve Developed* >

^{*All commercialization and marketing by AbbVie Inc.}

Uterine fibroids are most often seen in women between ages 30 to 40 but can occur at any age. Uterine fibroids are the most common pelvic growth, affecting around 20% of all women by age 59. Uterine fibroids are the leading cause of infertility.

Some common symptoms associated with uterine fibroids include heavy menstrual bleeding, painful periods, vaginal bleeding at times other than menstruation, anemia, pain in the abdomen or lower back, pain during sex, difficulty urinating or frequent urination, constipation, rectal pain, or difficulty getting pregnant.

See What We’ve Developed* >

^{*All commercialization and marketing by AbbVie Inc.}